Second-line chemotheraphy for non-small cell lung cancer: Recent data with pemetrexed

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Platinum-based chemotherapy offers a modest survival advantage over best supportive care (BSC) in chemotherapy-naive patients with a good performance status and advanced/metastatic non-small-cell lung cancer (NSCLC). Based on 2 landmark studies that reported improved survival times and quality of life when comparing docetaxel with ifosfamide, vinorelbine, or BSC alone, docetaxel at 75 mg/m2 given once every 3 weeks has been the standard of care as second-line chemotherapy since 2000. Docetaxel given at this dose and schedule resulted in significant hematologic toxicity, with many patients at risk for neutropenic fever. Pemetrexed is a novel multitargeted antifolate agent with single-agent activity in first- and second-line treatment of NSCLC. A phase III study in 571 patients comparing pemetrexed with docetaxel demonstrated clinically equivalent therapeutic outcomes in second-line treatment of patients with recurrent NSCLC; however, patients on the pemetrexed arm had a more favorable hematologic toxicity profile, with fewer episodes of neutropenia, neutropenic fever, and infections and less use of granulocyte colony-stimulating factor support. Based on these data, pemetrexed is a reasonable second-line chemotherapy option for patients with recurrent, advanced NSCLC.

Original languageEnglish
JournalClinical Lung Cancer
Volume5
Issue numberSUPPL. 2
StatePublished - Apr 2004

Fingerprint

Pemetrexed
docetaxel
Non-Small Cell Lung Carcinoma
Drug Therapy
Fever
Folic Acid Antagonists
Ifosfamide
Survival
Granulocyte Colony-Stimulating Factor
Standard of Care
Neutropenia
Platinum
Appointments and Schedules
Therapeutics
Quality of Life

Keywords

  • Best supportive care
  • Docetaxel
  • Gefitinib
  • Ifosfamide
  • Multitargeted antifolate
  • Recurrent lung cancer
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

Second-line chemotheraphy for non-small cell lung cancer : Recent data with pemetrexed. / Hanna, Nasser.

In: Clinical Lung Cancer, Vol. 5, No. SUPPL. 2, 04.2004.

Research output: Contribution to journalArticle

@article{b23a90d464374ac7ada144ddf7b09c55,
title = "Second-line chemotheraphy for non-small cell lung cancer: Recent data with pemetrexed",
abstract = "Platinum-based chemotherapy offers a modest survival advantage over best supportive care (BSC) in chemotherapy-naive patients with a good performance status and advanced/metastatic non-small-cell lung cancer (NSCLC). Based on 2 landmark studies that reported improved survival times and quality of life when comparing docetaxel with ifosfamide, vinorelbine, or BSC alone, docetaxel at 75 mg/m2 given once every 3 weeks has been the standard of care as second-line chemotherapy since 2000. Docetaxel given at this dose and schedule resulted in significant hematologic toxicity, with many patients at risk for neutropenic fever. Pemetrexed is a novel multitargeted antifolate agent with single-agent activity in first- and second-line treatment of NSCLC. A phase III study in 571 patients comparing pemetrexed with docetaxel demonstrated clinically equivalent therapeutic outcomes in second-line treatment of patients with recurrent NSCLC; however, patients on the pemetrexed arm had a more favorable hematologic toxicity profile, with fewer episodes of neutropenia, neutropenic fever, and infections and less use of granulocyte colony-stimulating factor support. Based on these data, pemetrexed is a reasonable second-line chemotherapy option for patients with recurrent, advanced NSCLC.",
keywords = "Best supportive care, Docetaxel, Gefitinib, Ifosfamide, Multitargeted antifolate, Recurrent lung cancer, Vinorelbine",
author = "Nasser Hanna",
year = "2004",
month = "4",
language = "English",
volume = "5",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Second-line chemotheraphy for non-small cell lung cancer

T2 - Recent data with pemetrexed

AU - Hanna, Nasser

PY - 2004/4

Y1 - 2004/4

N2 - Platinum-based chemotherapy offers a modest survival advantage over best supportive care (BSC) in chemotherapy-naive patients with a good performance status and advanced/metastatic non-small-cell lung cancer (NSCLC). Based on 2 landmark studies that reported improved survival times and quality of life when comparing docetaxel with ifosfamide, vinorelbine, or BSC alone, docetaxel at 75 mg/m2 given once every 3 weeks has been the standard of care as second-line chemotherapy since 2000. Docetaxel given at this dose and schedule resulted in significant hematologic toxicity, with many patients at risk for neutropenic fever. Pemetrexed is a novel multitargeted antifolate agent with single-agent activity in first- and second-line treatment of NSCLC. A phase III study in 571 patients comparing pemetrexed with docetaxel demonstrated clinically equivalent therapeutic outcomes in second-line treatment of patients with recurrent NSCLC; however, patients on the pemetrexed arm had a more favorable hematologic toxicity profile, with fewer episodes of neutropenia, neutropenic fever, and infections and less use of granulocyte colony-stimulating factor support. Based on these data, pemetrexed is a reasonable second-line chemotherapy option for patients with recurrent, advanced NSCLC.

AB - Platinum-based chemotherapy offers a modest survival advantage over best supportive care (BSC) in chemotherapy-naive patients with a good performance status and advanced/metastatic non-small-cell lung cancer (NSCLC). Based on 2 landmark studies that reported improved survival times and quality of life when comparing docetaxel with ifosfamide, vinorelbine, or BSC alone, docetaxel at 75 mg/m2 given once every 3 weeks has been the standard of care as second-line chemotherapy since 2000. Docetaxel given at this dose and schedule resulted in significant hematologic toxicity, with many patients at risk for neutropenic fever. Pemetrexed is a novel multitargeted antifolate agent with single-agent activity in first- and second-line treatment of NSCLC. A phase III study in 571 patients comparing pemetrexed with docetaxel demonstrated clinically equivalent therapeutic outcomes in second-line treatment of patients with recurrent NSCLC; however, patients on the pemetrexed arm had a more favorable hematologic toxicity profile, with fewer episodes of neutropenia, neutropenic fever, and infections and less use of granulocyte colony-stimulating factor support. Based on these data, pemetrexed is a reasonable second-line chemotherapy option for patients with recurrent, advanced NSCLC.

KW - Best supportive care

KW - Docetaxel

KW - Gefitinib

KW - Ifosfamide

KW - Multitargeted antifolate

KW - Recurrent lung cancer

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=2342612162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342612162&partnerID=8YFLogxK

M3 - Article

C2 - 15117429

AN - SCOPUS:2342612162

VL - 5

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - SUPPL. 2

ER -